Uber (UBER) has stabilised its total AI spending after exceeding its IT budget in Q1, Axios reports
Newsquawk Staff ·
Uber (UBER) has stabilised its total AI spending after exceeding its IT budget in Q1, Axios reports.
What it means
Reports of this kind, a company acknowledging it overshot a budget line and then stabilising it, sit in the genre of cost-discipline disclosure that has recurred across large US corporates since AI infrastructure spending began crowding into IT budgets. The pattern in comparable episodes is that the overrun itself draws less sustained attention than what it implies about planning: whether the breach reflects one-off project timing or a structural underestimate of AI-related costs, and whether the stabilisation is real discipline or deferred spend. The channel into the equity is through operating leverage and margin trajectory rather than revenue, since ground transport names like Uber are valued on conversion of gross bookings into profit and free cash flow, and uncontrolled opex challenges that narrative. Attribution to a press report rather than a company filing means the detail is unverified, and the customary sequence is for sell-side models to await the next scheduled results for confirmation of the spending path. Follow-ons worth noting are any comment from management on the cadence of AI investment and whether peers in the space report similar budget pressure.
Sources
- Kimi K3.1 Pro AI model builds GTA VI-style (TTWO) playable game demo in just 10 hours for USD 52, developer claims on X; showcases AI’s ability to generate video game experiences - UNCONFIRMED
- OpenAI expects future AI models to be capable of identifying and exploiting vulnerabilities that are currently unknown, according to a blog post
- Daily US Earnings Estimates: 26th October 2026: VZ, WELL
- US EQUITY OPEN: Breadth poor at the open: Energy leads gains on oil rally, Tech sees slight bounce
- Anthropic and Hg have agreed to form an independent consultancy Co. targeting corporate clients, FT reports citing sources
Related headlines
- Daily US Equity Opening News: SPCX explores access to 80K US cell sites; OpenAI nears USD 30bln funding at $1.25T valuation7 hours ago
- Oracle (ORCL) to invest USD 1bln in partner ecosystem over 4 years8 hours ago
- Newsquawk Weekly Economic Release 26th - 30th October 2026 6 hours ago
- US FDA approves subcutaneous induction regimen for AbbVie’s (ABBV) Skyrizi for adults with moderately to severely active Crohn’s disease42 min ago
- Texas Attorney General Ken Paxton sues OpenAI and CEO Sam Altman for lying to users and harming Texans1 hour ago
- The Trump administration plans to introduce voluntary “US Caught Seafood” labels to help consumers identify seafood origins, according to CBS4 hours ago
- Bristol Myers Squibb (BMY) spokesperson says the company has identified the cause of an earlier Car-T safety signal; will look to resume the paused trials in 20274 hours ago
- OpenAI reveals plans for an in-house exabyte-scale storage system4 hours ago
- Republican Senator Blackburn has raised concerns about Meta’s (META) plans to update its commercial terms, warning that the changes could “exploit American creators and businesses,” according to a letter4 hours ago
- CNBC speculates that Verizon (VZ) would most likely be involved in the context of a partnership with SpaceX (SPCX)5 hours ago
- Ukraine President Zelensky says the Tesla (TSLA)/SpaceX (SPCX) Starlink and Starshield service remains slowed5 hours ago
- Meta (META) says it will extend the implementation date of updated commercial terms to November 20th (prev. October 30th); extension will allow it to explain the changes to partners and stakeholders6 hours ago
- Abbott (ABT) presents new ESMO data showing 30% absolute improvement in sensitivity with the whole-genome sequencing Oncodetect test in colorectal cancer6 hours ago
- US BROKER MOVES: HESM upgraded at Raymond James; NCLH downgraded at JPM7 hours ago
- Bristol-Myers Squibb (BMY) says Iza-Bren reduced the risk of progression or death by 59% in Phase 3 breast cancer study; median PFS 8.2 months vs 4.0 months for chemotherapy; cORR 40.5% vs 20.2%; mDOR 6.9 vs 4.2 months8 hours ago